Skip to main content
. 2009 Dec 29;115(15):3008–3016. doi: 10.1182/blood-2009-08-231613

Table 4.

Grade 3 or 4 adverse events occurring in at least 5% of patients for the entire population by treatment arm

Grade 3 or 4 adverse event Arm A, concurrent R-EPOCH (n = 51), no. (%) Arm B, sequential EPOCH → R (n = 55), no. (%)
Neutropenia 22 (43) 22 (40)
Anemia 10 (22) 7 (13)
Thrombocytopenia 4 (8) 9 (16)
Febrile neutropenia 8 (16) 8 (15)
Infection 14 (27) 16 (29)
Neuropathy 0 3 (5)
Mucositis 1 (2) 4 (7)